Due to the promising results in bladder irrigations with high-dose ash mistletoe extract in superficial bladder cancer, a prospective, multicentre, two-arm, randomised study has been initiated [150]. The study involves 31 urological centres in Germany and one in Cairo. An overview can be found in a publication of the Arbeitsgemeinschaft Urologische Onkologie (working group urological oncology). The main study aim is to find out the time until a tumour occurs again. In addition, it is examined how safe and tolerable the therapy is, how likely a relapse is to occur or the disease is to progress after one year, whether the tumour changes in its aggressiveness and how quality of life develops.
Here, mistletoe therapy is compared to standard therapy (mitomycin). The follow-up period is 12 months. A total of 546 patients is to be included. If two thirds of the patients have reached the two-year study period (one year therapy, one year follow-up), an interim analysis is planned. If it is shown that one of the two therapies is significantly more successful than the other or that mistletoe therapy fails, the study will be terminated prematurely and the results will be published. You can read more about this study here.